CI

At a glance

ClinicalIndex Comparison Record
Phase 4Recruiting· 50 target
Drug / intervention
Paclitaxeldrug
Likely dose
Not stated in record
Key inclusion· 15
  • ✓Pathologically demonstrated breast cancer
  • ✓Candidate for neoadjuvant paclitaxel chemotherapy
  • ✓No concurrent investigational or commercial therapeutic agents with paclitaxel
  • ✓No metastatic disease on staging work-up
Key exclusion· 7
  • ✕Allergic reactions to paclitaxel or similar compounds
  • ✕Allergic reactions to Cremophor EL (polyoxyethylated castor oil)
  • ✕Known HIV infection
  • ✕Non-aspirin anticoagulation or documented bleeding disorders

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03096418
NCT03096418Phase 4RecruitingOn Track
Long Recruiting
CompareCT.gov

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

University of Wisconsin, Madison·interventional·Posted Mar 30, 2017·Updated Jun 16, 2026

In Brief

A Phase 4 clinical trial evaluating Paclitaxel for Breast Neoplasm Female. Currently recruiting, targeting 50 participants across 2 sites.

Detailed Summary

The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles 2-4 prior to surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasm Female
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 4Recruiting
20172018201920202021202220232024202520262027
First PostedMar 30, 2017
Enrollment StartMar 13, 2017
Primary CompletionJun 1, 2027
TodayJul 2, 2026
Enrollment to primary: 10.2 yearsPosted 9.3 years agoPrimary completion in 11 months

Interventions

Paclitaxeldrug

Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.